This “Opioid Related Disorder - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Opioid Related Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Opioid Related Disorder Understanding
Opioids are a class of drugs that bind with the opioid receptor present on the central nervous system in the brain and body to reduce the sensation of pain. Opioids predominantly include prescription pain relievers, synthetic opioids, and heroines. Symptoms can include nausea, vomiting, weakened immune system, clogged blood vessels, and hallucinations. Opioid Related Disorder is diagnosed by clinicians by taking history, evaluating symptoms, using clinical information to identify a problematic pattern of opioid related impairment and distress as well as using 11 diagnostic criteria mentioned in Diagnostic and Statistical Manual of Mental Disorders, fifth edition. An effective treatment for Opioid Related Disorder generally includes pharmacotherapy. Three FDA approved medications present for the treatment of individuals with Opioid Related Disorder are naltrexone, methadone, and buprenorphine.
"Opioid Related Disorder - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid Related Disorder pipeline landscape is provided which includes the disease overview and Opioid Related Disorder treatment guidelines. The assessment part of the report embraces, in depth Opioid Related Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Related Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Opioid Related Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Opioid Related Disorder.
This segment of the Opioid Related Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
OPNT003 is a nasal nalmefene and is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication that could be especially useful in treating overdose by high-potency synthetic opioids, such as fentanyl. The development of OPNT003 is supported by grants from the NIH and the BARDA. The Company plans to file a 505(b)(2) New Drug Application for OPNT003 with the U.S. Food and Drug Administration by the end of 2021.
ASP8062 is an orally active γ-amino-butyric acid type B (GABA B) receptor positive allosteric modulator. The drug is in Phase II clinical studies for the treatment of opioid related disorder. In July 2020, Astellas Pharma announced it had been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) in the US to help fund two Phase I clinical studies to evaluate the safety and efficacy of ASP8062 as an add-on maintenance therapy for opioid use disorder.
This segment of the report provides insights about the different Opioid Related Disorder drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 40+ key companies which are developing the therapies for Opioid Related Disorder. The companies which have their Opioid Related Disorder drug candidates in the most advanced stage, i.e. Phase III include, Opiant Pharmaceuticals.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Opioid Related Disorder therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid Related Disorder drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 1-3 business days.
Geography Covered
- Global coverage
Opioid Related Disorder Understanding
Opioid Related Disorder: Overview
Opioids are a class of drugs that bind with the opioid receptor present on the central nervous system in the brain and body to reduce the sensation of pain. Opioids predominantly include prescription pain relievers, synthetic opioids, and heroines. Symptoms can include nausea, vomiting, weakened immune system, clogged blood vessels, and hallucinations. Opioid Related Disorder is diagnosed by clinicians by taking history, evaluating symptoms, using clinical information to identify a problematic pattern of opioid related impairment and distress as well as using 11 diagnostic criteria mentioned in Diagnostic and Statistical Manual of Mental Disorders, fifth edition. An effective treatment for Opioid Related Disorder generally includes pharmacotherapy. Three FDA approved medications present for the treatment of individuals with Opioid Related Disorder are naltrexone, methadone, and buprenorphine.
"Opioid Related Disorder - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid Related Disorder pipeline landscape is provided which includes the disease overview and Opioid Related Disorder treatment guidelines. The assessment part of the report embraces, in depth Opioid Related Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Related Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Opioid Related Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Opioid Related Disorder.
Opioid Related Disorder Emerging Drugs Chapters
This segment of the Opioid Related Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Opioid Related Disorder Emerging Drugs
OPNT003: Opiant Pharmaceuticals
OPNT003 is a nasal nalmefene and is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication that could be especially useful in treating overdose by high-potency synthetic opioids, such as fentanyl. The development of OPNT003 is supported by grants from the NIH and the BARDA. The Company plans to file a 505(b)(2) New Drug Application for OPNT003 with the U.S. Food and Drug Administration by the end of 2021.
ASP8062: Astellas Pharma
ASP8062 is an orally active γ-amino-butyric acid type B (GABA B) receptor positive allosteric modulator. The drug is in Phase II clinical studies for the treatment of opioid related disorder. In July 2020, Astellas Pharma announced it had been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) in the US to help fund two Phase I clinical studies to evaluate the safety and efficacy of ASP8062 as an add-on maintenance therapy for opioid use disorder.
Opioid Related Disorder: Therapeutic Assessment
This segment of the report provides insights about the different Opioid Related Disorder drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Opioid Related Disorder
There are approx. 40+ key companies which are developing the therapies for Opioid Related Disorder. The companies which have their Opioid Related Disorder drug candidates in the most advanced stage, i.e. Phase III include, Opiant Pharmaceuticals.
Phases
This report covers around 40+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Opioid Related Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Opioid Related Disorder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Opioid Related Disorder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid Related Disorder drugs.
Opioid Related Disorder Report Insights
- Opioid Related Disorder Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Opioid Related Disorder Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Opioid Related Disorder drugs?
- How many Opioid Related Disorder drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Opioid Related Disorder?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Opioid Related Disorder therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Opioid Related Disorder and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Astellas Pharma
- Opiant Pharmaceuticals
- Nasus Pharma
- GW Pharmaceuticals
- Benuvia Therapeutics
- MediciNova
- DemeRx
- BioXcel Therapeutics
- ADial Pharmaceuticals
- Orexo
- Alar Pharmaceuticals
- BioCorRx
- Revive Therapeutics
- Vivera Pharmaceuticals
Key Products
- ASP8062
- OPNT003
- NS-001
- Cannabidiol
- Buprenorphine/naloxone sublingual
- Ibudilast
- DMX-1002
- AD-04
- Dexmedetomidine
- OX-124
- ALA-1000
- BICX-104
- Psilocybin
- Cannabidiol
This product will be delivered within 1-3 business days.
Table of Contents
IntroductionExecutive Summary
Opioid Related Disorder: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Opioid Related Disorder - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
OPNT003: Opiant Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
ASP8062: Astellas Pharma
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
DMX-1002: DemeRx
- Product Description
- Research and Development
- Product Development Activities
Preclinical/Discovery Stage Products
- Comparative Analysis
Psilocybin: Revive Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Opioid Related Disorder Key Companies
Opioid Related Disorder Key Products
Opioid Related Disorder- Unmet Needs
Opioid Related Disorder- Market Drivers and Barriers
Opioid Related Disorder- Future Perspectives and Conclusion
Opioid Related Disorder Analyst Views
AppendixList of Tables
Table 1 Total Products for Opioid Related Disorder
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Opioid Related Disorder
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Astellas Pharma
- Opiant Pharmaceuticals
- Nasus Pharma
- GW Pharmaceuticals
- Benuvia Therapeutics
- MediciNova
- DemeRx
- BioXcel Therapeutics
- ADial Pharmaceuticals
- Orexo
- Alar Pharmaceuticals
- BioCorRx
- Revive Therapeutics
- Vivera Pharmaceuticals
